This site is intended for healthcare professionals

FDA approves Kalydeco as first and only CFTR modulator to treat eligible infants with CF as early as four months of age.- Vertex

Read time: 1 mins
Last updated:28th Sep 2020
Published:26th Sep 2020
Condition: Cystic Fibrosis-CFTR
Type: drug
Register free for full access to